Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

Investment Rating - The report adjusts the investment rating to "Recommended" with a target price of 7.8 CNY [2][8] Core Views - The company is facing operational pressure with a significant decline in revenue and net profit for 2024, but there are signs of improvement in Q1 2025 [2][8] - The company has been focusing on R&D and innovation to diversify its product offerings, which is expected to enhance its resilience and future growth potential [8] Financial Performance Summary - For 2024, the company reported total revenue of 1.255 billion CNY, a year-on-year decrease of 21.45%, and a net profit of 109 million CNY, down 61.58% [2][4] - In Q1 2025, the company achieved revenue of 352 million CNY, a slight increase of 1.06% year-on-year, while net profit was 76.48 million CNY, down 27.57% [2][4] - The gross margin for 2024 was 53.86%, a decline of 5.33 percentage points, marking the lowest level since 2011 [8] Revenue and Profit Forecast - Projected revenues for 2025, 2026, and 2027 are 1.514 billion CNY, 1.750 billion CNY, and 2.018 billion CNY, respectively, with expected growth rates of 20.6%, 15.6%, and 15.3% [4][8] - Forecasted net profits for the same years are 197 million CNY, 250 million CNY, and 316 million CNY, with growth rates of 80.7%, 27.2%, and 26.2% [4][8] Product Development and Market Strategy - The company is actively investing in R&D to develop new products across various categories, including non-oral vaccines and pet vaccines, which is expected to diversify its product matrix and improve its market position [8] - The company aims to reduce reliance on a single product line, particularly the foot-and-mouth disease vaccine, which has seen significant sales declines [8]

Investment Rating - The report adjusts the investment rating to "Recommendation" for the company, with a target price of 15.3 CNY, reflecting a 30 times PE for 2025 [1][7]. Core Views - The company's main business is gradually recovering, with significant performance in the pet business. The report predicts a net profit of 177 million CNY for 2025 and 211 million CNY for 2026, with an EPS of 0.51 CNY and 0.61 CNY respectively [1][7]. Financial Performance Summary - In 2024, the company achieved a revenue of 1,043 million CNY, a year-on-year decrease of 16.77%, and a net profit of 93 million CNY, down 46.82%. In Q1 2025, revenue was 279 million CNY, up 18.32%, with a net profit of 53 million CNY, up 93.75% [1][3]. - The company’s revenue breakdown for 2024 shows a decline in pig vaccines by 22.58% to 336 million CNY, while poultry vaccines increased by 3.31% to 429 million CNY. The pet business saw a remarkable growth of 125.16%, totaling 46.21 million CNY [1][7]. - The gross margin for 2024 was 61.09%, with a slight increase in poultry vaccines' margin, while the net profit margin in Q1 2025 improved to 18.99%, up 7.39 percentage points year-on-year [1][7]. Business Segment Analysis - The report highlights that the pig vaccine segment is under pressure, but the poultry vaccine segment is accelerating. The pet business is performing exceptionally well, with significant contributions from new products like the cat trivalent vaccine [1][7]. - The company has maintained effective cost control, with a reduction in sales, management, and R&D expense ratios in Q1 2025 compared to the previous year [1][7]. Research and Development - The company continues to invest in R&D, enhancing its product matrix with new vaccines and medications, which are expected to help combat industry competition and drive growth [1][7].